Recurrent Fallopian Tube Endometrioid Adenocarcinoma
6 clinical trials · Condition
◉ Watch Recurrent Fallopian Tube Endometrioid Adenocarcinoma
| Record | Firm | Date |
|---|---|---|
| Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy (NCT05295589) | National Cancer Institute (NCI) | 2022-06-30 |
| Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (NCT04739800) | National Cancer Institute (NCI) | 2021-06-10 |
| Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer (NCT04034927) | National Cancer Institute (NCI) | 2019-12-04 |
| Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02839707) | National Cancer Institute (NCI) | 2017-06-23 |
Track Recurrent Fallopian Tube Endometrioid Adenocarcinoma automatically
Every clearance here is in the API, with alerts when new ones post.